Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan,1996

Abstract

Background

High usage of the neuraminidase inhibitor (NAI) oseltamivir in Japan since 2003 led the Neuraminidase Inhibitor Susceptibility Network to assess the susceptibility of community isolates of influenza viruses to oseltamivir and zanamivir.

Methods

Isolates were tested by the enzyme inhibition assay and by neuraminidase (NA) sequence analysis.

Results

Among 1,141 A(H3N2) viruses and 171 type B viruses collected in Japan during the 2003–2004 season, 3 (0.3%) A(H3N2) isolates showed high 50% inhibitory concentrations (IC₅₀) to oseltamivir. Each possessed a known resistance NA mutation at R292K or E119V. During the 2004–2005 season, no resistance was found among 567 influenza A(H3N2) or 60 A(H1N1) isolates, but 1 of 58 influenza B isolates had an NAI resistance mutation (D197N). Sequence analysis found that 4 (3%) of 132 A(H1N1) viruses from 2005–2006 had known NA resistance mutations (all H274Y), but no additional resistant isolates were detected from that or the subsequent 2006–2007 season. Concurrent testing of a selection of 500 influenza B viruses from 2000 to 2006 showed significant variations between seasons in both oseltamivir and zanamivir IC₅₀ values, but no persistent increases over this period.

Conclusions

Our findings suggested possible low-level transmission of resistant variants from oseltamivir-treated patients in several seasons in Japan but no sustained reductions in NAI susceptibility or consistently increased frequency of detecting resistant variants for any strain or subtype, despite high levels of drug use. In particular, although oseltamivir-resistant A(H1N1) viruses with the H274Y mutation spread globally in 2007–2008, we found little evidence for increasing levels of resistant A(H1N1) variants in Japan in preceding years.

References

Wright

, Neumann

, Kawaoka

Orthomyxoviruses. In Knipe

D.M.

, Howley

P.M.

(Editors). Fields Virology. 5th ed. Philadelphia: Lippincott–Raven Press 2007; pp. 1691–1740.

World Health Organization. Pandemic (H1N1) 2009. (Accessed 7 August 2009.) Available from http://www.who.int/csr/disease/swineflu/en/index.html.

Hayden

F.G.

Pandemic influenza – is an antiviral response realistic?

Pediatr Infect Dis J 2004; 23: S262–S269.

Gani

, Hughes

, Fleming

, Griffin

, Medlock

, Leach

Potential impact of antiviral drug use during influenza pandemic.

Emerg Infect Dis 2005; 11: 1355–1362.

Hayden

F.G.

Amantadine and rimantadine – clinical aspects. In Richman

D.D.

(Editor). Antiviral Drug Resistance. John Wiley & Sons Ltd 1996; pp. 59–77.

Neuraminidase Inhibitor Susceptibility Network.

NISN statement on antiviral resistance in influenza viruses.

Wkly Epidemiol Rec 2004; 79: 306–308.

Bright

R.A.

, Medina

M.J.

, Xu

Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern.

Lancet 2005; 366: 1175–1181.

Bright

R.A.

, Shay

D.K.

, Shu

, Cox

N.J.

, Klimov

A.I.

Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States.

JAMA-Express; 2006; 295. (Updated 2 February 2006. Accessed 6 August 2009.) Available from http://jama.ama-assn.org/cgi/content/abstract/295.8.joc60020v1.

Deyde

V.M.

, Xu

, Bright

R.A.

Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide.

J Infect Dis 2007; 196: 249–257.

10.

Deyde

, Garten

, Sheu

, Gubareva

, Klimov

Reply to Saito, et al.

J Infect Dis 2008; 197: 632–633.

11.

Centers for Disease Control and Prevention (US). Interim guidance on antiviral recommendations for patients with novel influenza A (H1N1) virus infection and their close contacts. (Updated 6 May 2009. Accessed 7 August 2009.) Available from http://www.cdc.gov/h1n1flu/recommendations.htm.

12.

Neuraminidase Inhibitor Susceptibility Network.

Use of influenza antivirals during 2003–2004 and monitoring of neuraminidase inhibitor resistance.

Wkly Epidemiol Rec 2005; 80: 156.

13.

Hayden

Developing new antiviral agents for influenza yreatment: what does the future hold?

Clin Infect Dis 2009; 48 Suppl 1: S3–S13.

14.

Herlocher

M.L.

, Truscon

, Elias

Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets.

J Infect Dis 2004; 190: 1627–1630.

15.

Yen

H.L.

, Herlocher

L.M.

, Hoffmann

Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.

Antimicrob Agents Chemother 2005; 49: 4075–4084.

16.

Monto

A.S.

, McKimm-Breschkin

J.L.

, Macken

Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.

Antimicrob Agents Chemother 2006; 50: 2395–2402.

17.

Kiso

, Mitamura

, Sakai-Tagawa

Resistant influenza A viruses in children treated with oseltamivir: descriptive study.

Lancet 2004; 364: 759–765.

18.

Ward

, Small

, Smith

, Suter

, Dutkowski

Oseltamivir (Tamiflu^®) and its potential for use in the event of an influenza pandemic.

J Antimicrob Chemother 2005; 55 Suppl 1: i15–i21.

19.

McKimm-Breschkin

, Trivedi

, Hampson

Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.

Antimicrob Agents Chemother 2003; 47: 2264–2272.

20.

World Health Organization. Influenza A(H1N1) virus resistance to oseltamivir: last quarter 2007 to first quarter 2008. Preliminary summary and future plans. (Updated 13 June 2008. Accessed 6 August 2009.) Available from http://www.who.int/csr/disease/influenza/oseltamivir_summary/en/index.html.

21.

Lackenby

, Thompson

C.I.

, Democratis

The potential impact of neuraminidase inhibitor resistant influenza.

Curr Opin Infect Dis 2008; 21: 626–638.

22.

Wetherall

N.T.

, Trivedi

, Zeller

Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network.

J Clin Microbiol 2003; 41: 742–750.

23.

Buxton

R.C.

, Juo

R.R.

, Voyta

J.C.

, Tisdale

, Bethell

R.C.

Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir.

Anal Biochem 2000; 280: 291–300.

24.

Gubareva

L.V.

, Matrosovich

M.N.

, Brenner

M.K.

, Bethell

, Webster

R.G.

Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus.

J Infect Dis 1998; 178: 1257–1262.

25.

Neuraminidase Inhibitor Susceptibility Network.

Monitoring of neuraminidse inhibitor resistance among clinical influenza virus isolates in Japan during the 2003–2006 influenza seasons.

Wkly Epidemiol Rec 2007; 82: 149–150.

26.

McKimm-Breschkin

J.L.

, Blick

T.J.

, Sahasrabudhe

Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en.

Antimicrob Agents Chemother 1996; 40: 40–46.

27.

Pediatric Advisory Committee briefing document for Tamiflu. Tamiflu (RO 64-0796) PAC Briefing Document 2008. Hoffman–La Roche 2007; Nutley, NJ, USA. (Updated 20 November 2007. Accessed 6 August 2009.) Available from http://www.fda.gov/ohrms/dockets/AC/07/briefing/2007-4325b_02_15_Sponsor%20Background%20Package%20Roche.pdf.

28.

Ison

M.G.

, Gubareva

L.V.

, Atmar

R.L.

, Treanor

, Hayden

F.G.

Recovery of drug-resistant influenza virus from immunocompromised patients: a case series.

J Infect Dis 2006; 193: 760–764.

29.

Mishin

V.P.

, Hayden

F.G.

, Gubareva

L.V.

Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors.

Antimicrob Agents Chemother 2005; 49: 4515–4520.

30.

Gubareva

L.V.

, Kaiser

, Matrosovich

M.N.

, Soo-Hoo 30, Hayden

F.G.

Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.

J Infect Dis 2001; 183: 523–531.

31.

Hatakeyama

, Sugaya

, Ito

Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors.

JAMA 2007; 297: 1435–1442.

32.

World Health Organization. Influenza A(H1N1) virus resistance to oseltamivir - 2008/2009 influenza season, northern hemisphere. (Updated 21 March 2009. Accessed 6 August 2009.) Available from http://www.who.int/csr/disease/influenza/h1n1_table/en/index.html.

33.

Lackenby

, Hungnes

, Dudman

S.G.

Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe.

Euro Surveill 2008; 13: pii:8026.

34.

Sheu

T.G.

, Deyde

V.M.

, Okomo-Adhiambo

Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.

Antimicrob Agents Chemother 2008; 52: 3284–3292.

35.

Ives

J.A.L.

, Carr

J.A.

, Mendel

D.B.

The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.

Antiviral Res 2002; 55: 307–317.

36.

Q.M.

, Kiso

, Someya

Avian flu: isolation of drug-resistant H5N1 virus.

Nature 2005; 437: 1108.

37.

Yen

H.L.

, Ilyushina

N.A.

, Salomon

, Hoffmann

, Webster

R.G.

, Govorkova

E.A.

Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.

J Virol 2007; 81: 12418–12426.

38.

Hurt

A.C.

, Barr

I.G.

, Hartel

, Hampson

A.W.

Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.

Antiviral Res 2004; 62: 37–45.

39.

Treanor

J.J.

, Hayden

F.G.

, Vrooman

P.S.

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza.

JAMA 2000; 283: 1016–1024.

40.

Nicholson

K.G.

, Aoki

F.Y.

, Osterhaus

A.D.

Efficacy and safety of oseltamivir in treatment of acute influenza; a randomized controlled trial.

Lancet 2000; 355: 1845–1850.

41.

Whitley

R.J.

, Hayden

F.G.

, Reizinger

Oral oseltamivir treatment of influenza in children.

Pediatr Infect Dis J 2001; 20: 127–133.

42.

Hayden

F.G.

, Belshe

, Villanueva

Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without post-exposure prophylaxis.

J Infect Dis 2004; 189: 440–449.

43.

Hayden

F.G.

, Gubareva

L.V.

, Monto

A.S.

Inhaled zanamivir for preventing influenza in families.

N Engl J Med 2000; 343: 1282–1289.

44.

Herlocher

M.L.

, Truscon

, Fenton

Assessment of development of resistance to antivirals in the ferret model of influenza virus infection.

J Infect Dis 2003; 188: 1355–1361.

45.

Bouvier

N.M.

, Lowen

A.C.

, Palese

Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol.

J Virol 2008; 82: 10052–10058.

46.

Sugaya

, Mitamura

, Yamazaki

Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children.

Clin Infect Dis 2007; 44: 197–202.

47.

Gubareva

L.V.

, Webster

R.G.

, Hayden

F.G.

Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay.

Antiviral Res 2002; 53: 47–61.

48.

Shiraishi

, Mitamura

, Sakai-Tagawa

, Goto

, Sugaya

, Kawaoka

High frequency of resistant viruses harbouring different mutations in amantadine-treated children with influenza.

J Infect Dis 2003; 188: 57–61.

49.

Ferguson

N.M.

, Mallett

, Jackson

, Roberts

, Ward

A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community based use of antivirals.

J Antimicrob Chemother 2003; 51: 977–990.

50.

Regoes

R.R.

, Bonhoeffer

Emergence of drug-resistant influenza virus: population dynamical considerations.

Science 2006; 312: 389–391.

51.

Lipsitch

, Cohen

, Murray

, Levin

B.R.

Antiviral resistance and the control of pandemic influenza.

PLoS Med 2007 4: e15.

Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan,1996–2007

Abstract

Background

Methods

Results

Conclusions

References